 FALCONE ET AL DIG LIV DIS 2016.pdf | [High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: A case series and the state of art] | 281 kB |
Share on Facebook
High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: A case series and the state of art
Abstract
BACKGROUND:
In recent years, proton pump inhibitors (PPIs) have been investigated at high-dose to modulate tumour microenvironment acidification thus restoring chemotherapeutic sensitivity. Moreover, several clinical data supports the role of cytotoxic drugs at low-dose continuously delivered as anticancer therapy.
METHODS:
Clinical records of three patients affected with gastrointestinal cancer refractory to standard treatments, who had received a combination of high-dose rabeprazole and metronomic chemotherapy were reviewed.
RESULTS:
The first case, a 78-year-old man was treated for lung metastasis from colon adenocarcinoma. The second case, a 73-year-old man was treated for metastatic rectal cancer to the liver. The third one, a 68-year-old man, underwent the combination regimen for colon cancer with lung, liver and peritoneal metastases.
CONCLUSIONS:
Despite the failure of previous standard chemotherapy for metastatic disease, good clinical outcome was shown in these patients treated with an unconventional association of high-dose PPIs and metronomic chemotherapy.
https://www.ncbi.nlm.nih.gov/pubmed/27651344
